| Literature DB >> 22511991 |
Roman A Perez1, Hae-Won Kim, Maria-Pau Ginebra.
Abstract
The vast majority of materials used in bone tissue engineering and regenerative medicine are based on calcium phosphates due to their similarity with the mineral phase of natural bone. Among them, calcium phosphate cements, which are composed of a powder and a liquid that are mixed to obtain a moldable paste, are widely used. These calcium phosphate cement pastes can be injected using minimally invasive surgery and adapt to the shape of the defect, resulting in an entangled network of calcium phosphate crystals. Adding an organic phase to the calcium phosphate cement formulation is a very powerful strategy to enhance some of the properties of these materials. Adding some water-soluble biocompatible polymers in the calcium phosphate cement liquid or powder phase improves physicochemical and mechanical properties, such as injectability, cohesion, and toughness. Moreover, adding specific polymers can enhance the biological response and the resorption rate of the material. The goal of this study is to overview the most relevant advances in this field, focusing on the different types of polymers that have been used to enhance specific calcium phosphate cement properties.Entities:
Keywords: calcium phosphate cement; hydroxyapatite; polymer
Year: 2012 PMID: 22511991 PMCID: PMC3324842 DOI: 10.1177/2041731412439555
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.813
Some properties of calcium phosphate cements that can be improved by the incorporation of a polymeric phase and the corresponding polymers
| Property improved | Polymers associated in liquid phase | Polymers associated in powder phase |
|---|---|---|
| Setting time | Alginate | — |
| Chitin | ||
| PEG | ||
| Cohesion | Chitosan | — |
| Alginate | ||
| Silk | ||
| PEG | ||
| Injectability | Hyaluronate | — |
| Cellulose | ||
| Macroporosity | Soybean | Gelatin |
| Albumen | Polyesters | |
| Mechanical properties | Gelatin | Chitosan |
| Chitosan | Polyesters | |
| Chitin | ||
| Polyesters | ||
| PAA | ||
| Fibrin glue | ||
| Long-term degradation | — | Gelatin |
| Chitosan | ||
| Polyesters | ||
| Drug eluting system | Chitosan | Gelatin |
| Polyesters | Polyesters | |
| PAA | ||
| Biological response | Gelatin | Alginate |
| Collagen | Polyesters |
PEG: polyethylene glycol; PAA: polyacrylic acid.
Figure 1.Different strategies for incorporating polymers in CPCs. The polymer can be incorporated either in the liquid phases (A, B, and C) or in the powder phases (D and E). A represents the mixing of a polymeric solution with the CPC powder to obtain a set CPC, which has the polymer homogeneously distributed in the structure. B represents foaming of the liquid solution, which is then combined with the powder to obtain a set macroporous CPC. C represents the incorporation of a small amount of CPC powder in a big volume of polymer solution, upon which a slurry is formed and is then freeze–dried, resulting in a macroporous polymer–CPC scaffold. D represents the combination of the powder phase with polymer fibers to obtain a fiber-reinforced CPC. Moreover, the fibers may act as pore generators when degraded. E represents the combination of the powder phase with polymer MSs, which can act as controlled drug eluting systems and simultaneously generate macropores in the CPC.
CPC: calcium phosphate cement.
Description of the different natural and synthetic polymers incorporated into the liquid or the powder phase of the CPC
| Polymer name | % Weight/specifications | Liquid phase | CPC composition | CPC end product | L/P ratio | Main effect | References |
|---|---|---|---|---|---|---|---|
| Liquid phase | |||||||
| Natural polymers | |||||||
| Gelatin | 0%–20% | H2O or Na2HPO4 solution | α-TCP | HA | 0.40–0.80 | Foaming of the gelatin solution results in injectable self-setting gelatin–HA foams | 23, 25 |
| 5% | 10× PBS | α-TCP | HA | 1.2 | Increase in initial cell adhesion and proliferation | 37 | |
| 0%–10% | H2O | CaCO3–MCPM | HA | 0.55 | Increase in setting time. Small effect on cell proliferation. Decrease in mechanical properties | 38 | |
| 15% | H2O | α-TCP–DCPD | HA | 0.3 | Similar proliferation values, but enhanced primary osteoblast activation and ECM mineralization process | 39 | |
| 2%–10% | H2O | CaCO3–MCPM | HA | 0.4 | Increase in setting time. Higher mechanical properties for lowest gelatin concentration (2%) | 40 | |
| 20% | H2O | ACP–DCPD | HA | — | Increase in setting time. Decrease in mechanical properties | 41 | |
| 0%–20% | H2O | α-TCP–DCPD | HA | 0.3 | Faster final production. Increase in mechanical properties with increase in gelatin concentration | 42 | |
| 10% | H2O | α-TCP–DCPD | HA | 0.3–0.4 | Increase in compressive strength | 43 | |
| 0%–20% | H2O | α-TCP | HA | 0.28–0.5 | Increased mechanical properties when gelatin concentration up to 5% | 44 | |
| Collagen | 0%–5%; fibers (∅ = 0.1–3 µm; L = 20–100 µm) | H2O | TTCP–DCPA | HA | 0.25–0.4 | Increase in cell adhesion. Decrease in compressive strength as collagen percentage was increased | 45 |
| 3% | 100–800 mM citric acid | MCPM–β-TCP | DCPD | 0.29 | Increase in cell adhesion. Mechanical properties maintained similar to control | 46 | |
| 0%–2% | H2O/0.2 M N2HPO4 | TTCP–DCPA | HA | 0.29 | Increase in setting times. Decrease in compressive strength as collagen percentage was increased | 47 | |
| Chitosan | 20% | H2O | ACP–DCPD | HA | 0.2 | Increase in setting times. Decrease in compressive strength | 41 |
| 0%–20% | H2O | TTCP–DCPA | HA | 0.5 | Increase in setting time. Increase in flexural strength | 48 | |
| 40% | Glycerol and Ca(OH)2 | TTCP–DCPA | HA | 0.5 | Increase in setting time. Increased antiwashout properties. Increase in diametral tensile strength. No cell cytotoxicity | 49 | |
| 0%–6% | 1 M phosphate buffer | MCPM–CaO | HA | 0.44–1.04 | Increase in compressive strength for low chitosan percentage. Decrease in compressive strength higher than 3% | 50 | |
| 0%–15% | 1 M Na2HPO4 | DCPD–Ca(OH)2 | HA | 0.44–1.04 | Increase in setting times. Increase in compressive strength as chitosan percentage is increased | 50 | |
| 0%–8% | 0.15 g MgCO3 + 0.18 mL 30 wt.% H3PO4 | α-TCP or TTCP | HA | 0.125 | Conversion to HA inhibited by large amounts of chitosan | 51 | |
| 0%–30% | H2O | TTCP–DCPA | HA | 0.5 | Reduction in setting times. Increase in flexural strength up to 20 wt.% chitosan | 52 | |
| 0%–15% | H2O | TTCP–DCPA | HA | 0.22–0.5 | Increase in flexural strength. No significant effect on cell activity | 53–58 | |
| 0%–15% | H2O | TTCP–DCPA | HA | 0.5 | Increase in flexural strength. Significant increase in ALP cell activity | 59, 60 | |
| 0%–15% | H2O | TTCP–DCPA | HA | 0.5 | Increase in flexural strength | 61 | |
| 2% | 1.5% Acetic acid solution | α-TCP | HA | 0.33 | Increase in compressive strength. No cell cytotoxicity. Bigger osteoclastic cell morphology | 62 | |
| 0%–15% | 5% Malic and malonic acid | β-TCP, CaO, MgO, ZnO. TTCP–DCPA | HA | 0.7 | Increase antiwashout properties. No significant effect on injectability | 63–67 | |
| 0%–12% | 1 M Na2HPO4 | MCPM–CaO or DCPD–Ca(OH)2 | HA | 0.96 or 2.29 | Negative effect of chitosan on biodegradation | 68 | |
| 0%–15% | PBS with 0–100 ng/mL protein A solutions | TTCP–DCPA | HA | 0.25–0.5 | Sustained release of gentamicin | 69 | |
| Alginate | 2.2% | 0.2 M neutral phosphate solution | TTCP–DCPA | HA | 0.29 | Increase in setting time. No significant effect of alginate on compressive strength up to 10% concentration | 70 |
| 2% | 0.2 M neutral phosphate solution | TTCP–DCPA | HA | 0.25 | No effect on setting time. Decrease in tensile diametral strength | 12 | |
| 0%–0.5% | 1 M Na2HPO4 | MCPM–CaCO3 incorporation of gentamicin 2.5% or 5% in powder | HA | 0.45 | Slight increase in setting time. Maximum strength unaffected. Extended release of gentamicin | 71 | |
| 20% | H2O | ACP–DCPD | HA | 0.2 | Increase in setting time. Decrease in mechanical properties | 41 | |
| 0%–6% | 2.5% Na2HPO4 | α-TCP | HA | 0.6–0.87 | Increase in setting time. Decrease in diametral tensile strength | 72 | |
| 0%–1% | 1% Na2HPO4 | α-TCP, DCPD, CaCO3, and PHA | HA | 0.35–0.40 | Reduction injectability | 14 | |
| 0%–1% | Chondroitin sulfate and succinic acid | α-TCP–TTCP–DCPD | HA | 0.3 | Increase in cohesion and antiwashout properties | 73 | |
| 0%–2% | 105 mM CaCl2 | ACP–DCPD (α-BSM) | HA | 0.8 | Support cell growth and osteogenesis | 74 | |
| Hyaluronate | 0%–0.5% | 0.5 M citric acid | β-TCP–MCPM | DCPD | 0.4 | Setting times were increased. Mechanical properties unaffected | 75 |
| 0%–8% | 2.5% Na2HPO4 | α-TCP | HA | 0.35 | No effect on mechanical properties | 76 | |
| 0%–1% | 0.2 M PBS | TTCP–DCPD | HA | 0.35 | Increased injectability | 77 | |
| Cellulose | 0%–2.2% | Na2HPO4 | TTCP–DCPA, α-TCP–CaCO3, DCPA–Ca(OH)2 | HA | 0.25 and 0.27 | Increase in setting time. Increase in mechanical properties | 78,79 |
| 0%–3% | 0.2 M sodium phosphate | TTCP–DCPA, TTCP–DCPD | HA | 0.5 | Similar setting times to control. Mechanical properties increased. Increase in injectability | 80 | |
| Silk | 0%–2% | 0.9 NaCl solution | ACP–DCPD (α-BSM) | HA | 0.8 | Decrease in compressive strengths | 74 |
| 0%–2% | 0.25 M NaHPO4/Na2HPO4 | α-TCP | HA | 0.4 | Increase in flexural strength. No difference in setting time or cell viability respect to control | 81 | |
| Chondroitin sulfate | 0%–20% | H2O and 0.5 M citric acid | ACP–DCPDa and β-TCP–MCPMb | HAa and DCPDb | 0.39–0.5 | Slightly higher setting times and mechanical properties | 41, 82 |
| Chitin | 0%–4% | H2O | α-TCP–TTCP–DCPD | HA | 0.43 | Reduction of setting times. Increase in compressive strength | 83 |
| Albumen | 0%–12% | H2O or Na2HPO4 solution | α-TCP | HA | 0.35 | Macroporous self-setting calcium phosphate foams are obtained. Faster resorption in vivo | 21, 22 |
| Soybean- derived hydrogel | 0%–20% | Na2HPO4 solution with or without gelatin | α-TCP | HA | 0.65 | Injectable calcium phosphate foams with an enhanced osteoblast adhesion growth | 24 |
| Synthetic polymers | |||||||
| Polyesters and polyethers | 0%–20% | 2% Alginate in H2O | PCCP–DCPA | HA | 0.31–1 | Scaffold immersed in PLGA solution. Increase in the mechanical properties in the presence of PLGA | 84 |
| 0%–3% | PEG in H2O | TTCP–DCPA | HA | 0.33 | Concentrations higher than 1% decreased mechanical properties | 85 | |
| 1.4% PPF | TTCP–DCPA | HA | 0–1 | Decrease in mechanical properties. Prolonged release of protein Rg1 | 86 | ||
| 0%–1% Liquid (polysorbate 20) | Glycerol | MCPM–β-TCP | DCPD | 0.21–0.44 | Since the paste is formed with glycerol, no water is contained and reaction does no start until immersed in water. Setting times and compressive strength similar to control | 87 | |
| — | PEG and glycerin | MCPM–β-TCP | DCPD | 0.27–0.4 | Increased setting times. Higher cohesion and antiwashout properties. Higher inflammatory response than control | 88 | |
| 0%–0.5% PEG and glycerin | Na2HPO4 and citric acid | ACP–DCPD | HA | 0.5 | Decrease in setting times. Reduced injectability | 89 | |
| 0%–10% Glycerol | Ca(OH)2, H3PO4, and H2O | α–TCP and TTCP | HA | 0.43 | Increase in setting time. Improvement of injectability and reduction in injecting force | 90 | |
| Polyacrylic acid | 0%–1.45% | 0.0625 g/mL Gentamicin sulfate | MCPM–β-TCP | DCPD | 0.8 | Controls the gentamicin release during prolonged time | 91, 92 |
| 0%–20% Acrylamide | 0.5% MBAM, 0.25% 0.30 mL/g TEMED, 2.5% Na2HPO4, and 1% PA | α-TCP | HA | 0.30–0.32 | Significant increase in the compressive and tensile strength. Reduction of the porosity | 93 | |
| 35% Polymethyl-vinyl ether-maleic acid or 10% polyacrylic acid | H2O | TTCP–DCPD–TCP | HA | 0.25 | Considerable increase in compressive strength, even at short times. Lower cell viability than control after 24 h. After 1 week, similar cell viability to control | 94 | |
| Fibrin glue | — | Fibrin glue (Hualan Biological Engineering, China) | TTCP–DCPA | HA | 0.2–1 | Increase in setting times. Considerable increase in compressive strength. No effect on cell proliferation and differentiation after 14-day culture | 95 |
| Solid phase | |||||||
| Natural polymers | |||||||
| Gelatin MS | 0%–10%; MS size 15.48–8.64 µm; bFGF, TGF-β1 and BMP2 incorporated | 1% Na2HPO4 | α–TCP–DCPA–CaCO3 | HA | 0.91 | Setting time and macroporosity were increased. Compression strength was decreased. Prolonged release of growth factors was obtained | 96–98 |
| Gelatin MS | 10%; 50–150 µm. Gentamicin incorporated in MS (900 mg) | 1% Na2HPO4 | α–TCP–MCPM–CaCO3 | HA | 0.4 | Incorporation of MS increased setting times and porosity. Compressive strength was decreased, but could be enhanced by the incorporation of calcium sulfate hydrate. Release of gentamicin can be controlled depending on cross-link of MS | 99 |
| Gelatin MS | 5%; 20 µg of BMP2 incorporated in implant | 1 M Na2HPO4 | TTCP–DCPA | HA | 0.45 | Release of BMP2 is more prolonged when BMP2 is incorporated in gelatin MS. Can accelerate healing osteoporosis in vivo | 100 |
| Gelatin MS | 0%–5% | 1 M Na2HPO4 | TTCP–DCPA | HA | 0.4 | The mechanical properties of composite initially increased but decrease with degradation. Increased macroporosity. Optimum amount is 2.5% of mass fraction MS. Good biocompatibility in vitro and in vivo | 101 |
| Gelatin MS | 48%–57%; size 37 ± 31 µm | 2% Na2HPO4 | α–TCP–DCPA | HA | 0.35 | Adequate degradation in vivo. Increased macroporosity | 102 |
| Collagen | 0%–5% | H2O/0.2 M neutral phosphate | TTCP–DCPA | HA | 0.29 | Prolonged setting times and reduced mechanical properties | 47 |
| Chitosan | 0%–2% | H2O | ACP–DCPD | HA | 0.5 | Setting times reduced. No effect on compressive strength | 103 |
| Cellulose | 0%–6.4% | 2.5% NaHPO4 | α-TCP | HA | 0.6–0.87 | Increase in injectability | 104 |
| Alginate microbeads | 1.2% sodium alginate; 0%–70% microbeads; size 207 µm | 15% Chitosan in H2O | TTCP–DCPA | HA | 0.25 | Decrease in flexural strength. Cells were able to survive, proliferate, and differentiate | 105–108 |
| Alginate | 0%–1% | H2O | ACP–DCPD | HA | 0.5 | Setting times decreased. Compressive strength decreased as polymer concentration increased. Injectability reduced | 103 |
| Synthetic polymers | |||||||
| PLGA microspheres | 20%; Microspheres 10–110 µm diameter | 2% Na2HPO4 BMP2 adsorbed and entrapped on microparticles | α-TCP, DCPA, and CaCO3 | HA | 0.35–0.5 | Controlled degradation of PLGA allows for a prolonged release of the BMP2. In vitro and in vivo were shown to be biocompatible and the presence of the microparticles allowed to obtain interconnected porosity for tissue ingrowth | 26, 109–114 |
| PLGA MS | 5%; MS size 7–14 µm; gentamicin or BMP2 loading | H2O or 4% Na2HPO4 | TTCP–DCPA | HA | 0.3 | Controlled and prolonged release of growth factor. No change of the setting times or the mechanical performance | 115, 116 |
| PGA fibers | 0%–45%; fraction volume fiber length 8 mm | 15% Chitosan solution or H2O | TTCP–DCPA or TTCP–DCPD | HA | 0.22–0.4 | Material exceeded strength of cancellous bone. Increased flexural strength. Cells presented excellent viability, differentiated, and synthesized bone minerals | 117–120 |
| PCL and PLLA fibers | 0%–7%; fibers 3 mm | 1% Na2HPO4 | α-TCP, DCPA, and CaCO3 | HA | 0.33 | Connective channel-like porous structure was created in the CPC. Toughness was improved. Decreased flexural strength | 121 |
| PGA fibers | 0%–24%; diameter 0.30–0.349 mm | 3.5 M H3PO4 + 100 mM sodium citrate | β-TCP (Plasma Biotal, UK) | DCPD | 0.67 | The yield and ultimate strength increased. Modulus of elasticity also increased in flexural testing. Regular fiber orientation led to higher mechanical properties compared to random fibers | 122 |
| Aramide fibers | 0%–9.5%; fraction volume fiber length 3–200 mm | H2O | TTCP–DCPA | HA | 0.33 | Ultimate strength significantly increased. The longer the fibers, the higher the mechanical properties | 123 |
| Polyamide fibers | 0%–1.6%; diameter 0.1 mm and length 3 mm | 2.5% NaHPO4 | α-TCP | HA | 0.55 | Increase in compression strength, but was not concentration dependent | 124 |
| Polyacrylic acid | 0%–25%; 45- to 75-µm particles | H2O | TTCP–DCPA | HA | 0.4 | Increase in setting time proportional to increase in concentration. Significant increase in the compressive strength | 125 |
CPC: calcium phosphate cement; L/P: liquid to powder; TCP: tricalcium phosphate; HA: hydroxyapatite; PBS: phosphate buffered saline; MCPM: monocalcium phosphate monohydrate; DCPD: dicalcium phosphate dehydrate; ECM: extracellular matrix; ACP: amorphous calcium phosphate; TTCP: tetracalcium phosphate; DCPA: dicalciumphoshphate anhydrous; ALP: alkaline phosphatase; PHA: precipitated hydroxylapatite; PCCP: partially crystallized calcium phosphate; PLGA: poly(lactic-co-glycolic acid); PEG: polyethylene glycol; PPF: poly(propylene fumarate); MBAM: N,N′-methylenebisacrylamide; TEMED: N,N,N′N′-tetramethylethylenediamide; PA: polyacrylate; MS: microsphere; TGF: transforming growth factor; BMP2: bone morphogenetic protein 2; PGA: polyglycolide acid; PCL: poly(ϵ-caprolactone); PLLA: poly(l-lactic acid); bFGF: basic fibroblast growth factor.